

Date: May 9, 2025

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai – 400001
Scrip Code: 543064

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400051
Scrip Symbol: SUVENPHAR

Sub: Disclosure under Regulation 10(6) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (“SEBI Takeover Regulations”)

Ref: Scheme of Amalgamation of Cohance Lifesciences Limited (“Transferor Company” / “Cohance”) with and into Suven Pharmaceuticals Limited (“Transferee Company” / “the Company” / “TC”) under Sections 230 to 232 of the Companies Act, 2013 (“Act”), the Companies (Compromises, Arrangements and Amalgamations) Rules, 2016 and other rules and regulations framed thereunder (“Scheme of Amalgamation”)


Dear Sir/Madam,

Pursuant to Regulation 10(6) of the SEBI Takeover Regulations, we enclose herewith disclosure with respect to allotment of shares by the Transferee Company, pursuant to the above-referred Scheme of Amalgamation.

We request you to please take the same on record.

Thanking you.

Yours faithfully,
For **Jusmiral Holdings Limited**


.....
Director

CC: Company Secretary, Cohance Lifesciences Limited (Formerly, Suven Pharmaceuticals Limited)

Disclosures under Regulation 10(6) –Report to Stock Exchanges in respect of any acquisition made in reliance upon exemption provided for in Regulation 10 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

1.	Name of the Target Company (TC)	Cohance Lifesciences Limited (Formerly, Suven Pharmaceuticals Limited)
2.	Name of the acquirer(s)	<p><u>Acquirer:</u> Jusmiral Holdings Limited</p> <p><u>Person acting in concert:</u> (a) Berhyanda Limited (b) Berhyanda Midco Limited (c) Jusmiral Midco Limited</p>
3.	Name of the stock exchange where shares of the TC are listed	BSE Limited and National Stock Exchange of India Limited
4.	Details of the transaction including rationale, if any, for the transfer/ acquisition of shares.	<p>This transaction is pursuant to the Scheme of Amalgamation, approved by the Hon'ble National Company Law Tribunal, Mumbai Bench, <i>vide</i> its order dated March 27, 2025.</p> <p>Further, pursuant to the said Scheme of Amalgamation the name of the Company i.e. “Suven Pharmaceuticals Limited” has also been changed to “Cohance Lifesciences Limited”, effective from May 7, 2025.</p> <p>The TC has allotted equity shares to the shareholders of the Transferor Company, in the ratio of 11 (eleven) fully paid-up equity shares of Re.1/- (Rupee one) each of the TC for every 295 (two hundred ninety-five) fully paid-up equity shares of Rs.10/- (Rupees Ten) each held by such shareholders in Transferor Company.</p> <p>Accordingly, TC has allotted 12,65,38,578 equity shares of Re. 1 each to Jusmiral Holdings Limited, who was promoter shareholder of the Transferor Company. Consequent to the said allotment of shares, Jusmiral Holdings Limited also forms part of the promoter group of TC.</p>
5.	Relevant regulation under which the acquirer is exempted from making open offer.	Regulation 10(1)(d)(ii) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (“SEBI Takeovers Regulations”)
6.	Whether disclosure of proposed acquisition was required to be made under regulation 10(5) and if so, - whether disclosure was made and whether it was made within the timeline specified under the regulations. - date of filing with the stock exchange.	Not applicable. The allotment of shares is pursuant to the said Scheme of Amalgamation approved by the Hon'ble National Company Law Tribunal, Mumbai Bench <i>vide</i> order dated March 27, 2025.


7.	Details of acquisition		Disclosures required to be made under regulation 10(5)		Whether the disclosures under regulation 10(5) are actually made	
	a.	Name of the transferor / seller	Not applicable		Not applicable	
	b.	Date of acquisition	Not applicable		Not applicable	
	c.	Number of shares/ voting rights in respect of the acquisitions from each person mentioned in 7(a) above	Not applicable		Not applicable	
	d.	Total shares proposed to be acquired / actually acquired as a % of diluted share capital of TC	Not applicable		Not applicable	
	e.	Price at which shares are proposed to be acquired / actually acquired	Not applicable		Not applicable	
8.	Shareholding details		Pre-Transaction		Post-Transaction	
			No. of shares held	% w.r.t total share capital of TC	No. of shares held	% w.r.t total share capital of TC
	a	Each Acquirer / Transferee(*) Acquirer - Jasmiral Holdings Limited	-	-	12,65,38,578	33.08
		Person acting in concert - Berhyanda Limited	12,75,39,592	50.10 [#]	12,75,39,592	33.34 [#]
		Total	12,75,39,592	50.10[#]	25,40,78,170	66.41
	b	Each Seller / Transferor	Not applicable. Please refer comments in Para 4 above			

[#] Pursuant to the Scheme of Amalgamation, TC has allotted equity shares to the shareholders of the Transferor Company, in the ratio of 11 (eleven) fully paid-up equity shares of Re.1/- (Rupee one) each of the TC for every 295 (two hundred ninety-five) fully paid-up equity shares of Rs.10/- (Rupees Ten) each held by such shareholders in Transferor Company. Consequent to allotment of shares by TC, the existing promoter, Berhyanda Limited, who was holding 50.10% equity share capital of TC (pre-merger allotment), is now holding 33.34% shares of TC (post-merger allotment).

Note:

- (*) Shareholding of each entity shall be shown separately and then collectively in a group.
- The above disclosure shall be signed by the acquirer mentioning date & place. In case, there is more than one acquirer, the report shall be signed either by all the persons or by a person duly authorized to do so on behalf of all the acquirers.

For **Jasmiral Holdings Limited**


.....
Director

Place: *Nicosia, Cyprus*
Date: **May 9, 2025**